Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: T-cell receptor protein therapeutics - ImmuVen

Next Previous
Search
Drug Profile

Research programme: T-cell receptor protein therapeutics - ImmuVen

Alternative Names: IMV-0123

Latest Information Update: 28 Jul 2018

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Illinois at Urbana-Champaign
  • Developer ImmuVen
  • Class Antibacterials; Antineoplastics; Recombinant fusion proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer; Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer(Diagnosis) in USA (Parenteral)
  • 02 May 2012 ImmuVen is awarded a phase II Small Business Innovation Research grant from the US NIAID to continue development of its lead therapeutic IMV0123, for the treatment of MRSA and MSSA infections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top